摘要
Background Category Ⅲ chronic prostatitis/chronic pelvic pain syndrome （CP/CPPS） is a common syndrome of unclear etiology with significant impact on quality of life. Because the outcomes of multiple therapies for CP/CPPS have been far from approving, the possible psychological factors have been considered to play an important role in CP/CPPS.Based on this, we investigated the role of antidepressant drug （fluoxetine） in men with refractory CP/CPPS.Methods In this study, 42 men diagnosed with refractory CP/CPPS without response to standard therapy （include multiple antibiotic courses and a-blockers） were referred for fluoxetine therapy. All patients received fluoxetine （20 mg/d） for three months and were clinically evaluated before （baseline）, and after 4, 8 and 12 weeks of therapy. The evaluation included a National Institutes of Health-chronic prostatitis symptom index （NIH-CPSI） and a Beck depression inventory （BDI） questionnaire. Moreover, the subjective global assessment （SGA） was assessed at the 4th, 8th and 12th week of therapy.Results Significant decreases were observed for total NIH-CPSI （28.55 to 9.29）, NIH-CPSI pain （14.69 to 5.19）,NIH-CPSI urinary （4.95 to 1.88 ）, NIH-CPSI quality of life （8.83 to 2.20）, and BDI （34.67 to 13.95） scores compared with baseline, all P values ＜0.05. Twenty-nine （69.05%） reported marked improvement on the subjective global assessment and 33 （78.57%） had a greater than 50% decrease in NIH-CPSI at the end of therapy （12th week）. At the same time, the Pearson correlation coefficient analysis demonstrated a positive correlation between BDI score and each CPSI score. No adverse events were reported in this study.Conclusions Fluoxetine appears to be a safe and effective treatment in improving symptoms in, and the quality of life of, men with difficult CP/CPPS. Moreover, amelioration of difficult CP/CPPS-related symptoms could be related to a decrease in depressive symptoms.
Background Category Ⅲ chronic prostatitis/chronic pelvic pain syndrome （CP/CPPS） is a common syndrome of unclear etiology with significant impact on quality of life. Because the outcomes of multiple therapies for CP/CPPS have been far from approving, the possible psychological factors have been considered to play an important role in CP/CPPS.Based on this, we investigated the role of antidepressant drug （fluoxetine） in men with refractory CP/CPPS.Methods In this study, 42 men diagnosed with refractory CP/CPPS without response to standard therapy （include multiple antibiotic courses and a-blockers） were referred for fluoxetine therapy. All patients received fluoxetine （20 mg/d） for three months and were clinically evaluated before （baseline）, and after 4, 8 and 12 weeks of therapy. The evaluation included a National Institutes of Health-chronic prostatitis symptom index （NIH-CPSI） and a Beck depression inventory （BDI） questionnaire. Moreover, the subjective global assessment （SGA） was assessed at the 4th, 8th and 12th week of therapy.Results Significant decreases were observed for total NIH-CPSI （28.55 to 9.29）, NIH-CPSI pain （14.69 to 5.19）,NIH-CPSI urinary （4.95 to 1.88 ）, NIH-CPSI quality of life （8.83 to 2.20）, and BDI （34.67 to 13.95） scores compared with baseline, all P values ＜0.05. Twenty-nine （69.05%） reported marked improvement on the subjective global assessment and 33 （78.57%） had a greater than 50% decrease in NIH-CPSI at the end of therapy （12th week）. At the same time, the Pearson correlation coefficient analysis demonstrated a positive correlation between BDI score and each CPSI score. No adverse events were reported in this study.Conclusions Fluoxetine appears to be a safe and effective treatment in improving symptoms in, and the quality of life of, men with difficult CP/CPPS. Moreover, amelioration of difficult CP/CPPS-related symptoms could be related to a decrease in depressive symptoms.
基金
This work was supported by the grants from the National Natural Science Foundation of China （No. 30973002） and Zhejiang Provincial Natural Science Foundation （No. Y2090099）.
